Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Nanotechnology. 2013 Jul 26;24(29):295102. doi: 10.1088/0957-4484/24/29/295102. Epub 2013 Jun 25.
Respiratory syncytial virus (RSV) is a major cause of pneumonia and wheezing in infants and the elderly, but to date there is no licensed vaccine. We developed a gold nanorod construct that displayed the major protective antigen of the virus, the fusion protein (F). Nanorods conjugated to RSV F were formulated as a candidate vaccine preparation by covalent attachment of viral protein using a layer-by-layer approach. In vitro studies using ELISA, electron microscopy and circular dichroism revealed that conformation-dependent epitopes were maintained during conjugation, and transmission electron microscopy studies showed that a dispersed population of particles could be achieved. Human dendritic cells treated with the vaccine induced immune responses in primary human T cells. These results suggest that this vaccine approach may be a potent method for immunizing against viruses such as RSV with surface glycoproteins that are targets for the human immune response.
呼吸道合胞病毒（RSV）是导致婴儿和老年人肺炎和喘息的主要原因，但目前尚无许可的疫苗。我们开发了一种金纳米棒构建体，该构建体展示了病毒的主要保护性抗原，即融合蛋白（F）。通过层层法使用病毒蛋白的共价附着，将与 RSV F 缀合的纳米棒配制成候选疫苗制剂。使用 ELISA、电子显微镜和圆二色性的体外研究表明，在缀合过程中保持了构象依赖性表位，并且透射电子显微镜研究表明可以实现分散的颗粒群体。用疫苗处理的人树突状细胞在原代人 T 细胞中诱导免疫反应。这些结果表明，这种疫苗方法可能是一种有效的方法，可用于针对人类免疫反应的靶标表面糖蛋白的 RSV 等病毒进行免疫接种。
